21st century business herald reporter Zhao Na intern Xiao Qian comprehensive report
Consumer service
A new generation of children’s snack brand Duomaomao completed tens of millions of A round financing.
On September 8 th, the new generation of children’s snack brand Duomaomao has completed tens of millions of A-round financing, which was jointly led by Houwei Capital (Mango Diyuan) and old shareholder Yiling Capital. This round of financing will be used for product research and development and channel laying.
Duomaomao was founded in September, 2020, and started with children’s jelly in the early days. At present, it has formed a product matrix of main and supplementary foods, snacks and condiments.
Bosie, a cutting-edge designer brand in China, completed a new round of financing of several hundred million yuan.
On September 7th, bosie, a cutting-edge designer brand, announced today that it has completed a new round of financing of several hundred million yuan. The investors are bilibili and Wuyuan Capital, and the old shareholder Jinshajiang Venture Capital is the sole financial advisor. This round of financing will be used for product development and supply chain upgrade.
Bosie is a non-sexist clothing brand, which is committed to bringing simple and generous classic items to young people who are exploring themselves and pursuing independence.
Medical health
Ruhan Gene completed tens of millions of angel rounds of financing.
On September 6th, Shenzhen Ruhan Gene Technology Co., Ltd. (hereinafter referred to as "Ruhan Gene") completed tens of millions of RMB angel round financing led by Lihe Kechuang Venture Capital, and the financing proceeds will be used for technology research and development, equipment procurement and team building.
Ruhan gene integrates the latest technologies such as bioengineering and genomics, semiconductor technology, AI big data analysis technology, micro-nano technology, etc., and develops the fourth-generation gene sequencing, nanopore virus detection and other biomacromolecule detection related equipment with independent intellectual property rights.
Zhenluo completed the B+ round financing of 100 million yuan scientifically
On September 6th, it was reported that Shenzhen Zhenluo Science Co., Ltd., the world’s leading innovative medical technology and service company in the field of central nervous system diseases, has recently completed a B+ round of financing of RMB 100 million. This round of financing was jointly led by Qiming Venture Capital and Stowe Capital, and F-Prime Capital followed suit. It is reported that the funds from this round of financing will be used for technical research, product development, international scientific research cooperation and global business development.
Zhenluo Science takes Parkinson’s disease as the market entry point of central nervous system diseases, and is committed to building a full-time diagnosis and treatment system based on advanced technology, providing innovative value for patients, clinical experts and medical equipment partners in this field.
Stance was led by CDH VGC in Series C with over $40 million.
On September 6th, Shanghai Stensai Biotechnology Co., Ltd. (hereinafter referred to as "Stensai") announced the completion of the Series C financing of over US$ 40 million. This round of financing was led by CDH VGC (CDH Innovation and Growth Fund), and many other investment institutions followed suit. This round of financing will be used for the research and development of innovative CoupleCAR platform technology, promote the development of cell therapy products for colorectal cancer and other solid tumors, and accelerate the clinical trial process in the United States and China.
Stance is a global cell therapy company, which is mainly engaged in the research and application of cutting-edge CAR-T technology and gene editing technology.
Weituo Bio, an assisted reproductive head enterprise, completed the C round of financing of 100 million yuan.
On September 7, Shenzhen Weituo Biotechnology Co., Ltd. (hereinafter referred to as Weituo Biotechnology) announced the completion of the C round of financing of 100 million yuan. It is reported that this round of financing was led by Zhongjin Qichen Fund, a subsidiary of CICC Capital, and Zhang Kehe Run and Xiang Financing followed suit. The favor of many professional investors reflects the high trust in the professional ability and strategic layout of Weituo Biological Team. This round of investment will be mainly used to strengthen product research and development, enrich product pipelines, expand professional teams and accelerate commercial landing, and further expand Weituo Bio’s leading edge in core technologies and markets.
Weituo Bio is committed to providing cutting-edge technology in the field of assisted reproduction and providing integrated solutions for assisted reproduction laboratories around the world.
RootPath completed nearly $50 million in Series B financing.
On September 7th, RootPath, a synthetic biology and gene cell therapy company, announced that it had recently completed a series B financing of nearly $50 million. This round of financing will be used for the development and commercialization of genetic synthesis products with arbitrary sequence Qualcomm quantity, long fragment and high accuracy, and for pushing its individualized TCR-T treatment project based on the technology of TCR gene synthesis and function verification with ultra-Qualcomm quantity to the clinical development stage, including the construction of GMP workshop suitable for IIT and Phase I clinical trials in China.
RootPath is a company that develops synthetic biology and cell therapy technology with the world’s leading gene synthesis platform.
"Good mood" completed the C round of 200 million yuan financing
On September 7th, "Good Mood" announced the completion of the 200-million-yuan Series C strategic financing. This round of financing was led by ByteDance, followed by Fosun Health, Decheng Capital and Xingfu Capital, and the old shareholders Tonghe Yucheng and KIP China were oversubscribed. This round of financing funds will be mainly invested in business expansion, intelligent supply chain construction, offline chain psychological clinics laying and data-based artificial intelligence product research and development, further consolidating the super-head position of mental health service industry and leading the development of the industry.
Good Mood is an Internet medical platform focusing on mental health services in CNS (Central Nervous System), which provides professional, advanced, efficient and convenient digital diagnosis and treatment services for patients with mental illness.
Mai Ruisheng completed tens of millions of yuan Series A financing.
On September 8, news, Jingmai Ruisheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as: Mai Ruisheng) announced the completion of tens of millions of A-round financing. The investor is Boqu Fund, where Fun Road Assets is the fund manager, and WinX Capital is the exclusive financial advisor. After the completion of this financing, Mindray will further build a CRO platform of "equipment+special medical food+medical beauty and health" by relying on its strong CRO capabilities.
With more than ten years’ experience in equipment CRO, Mindray Group is the largest CRO platform of "equipment+special medical food+medical beauty and health" in China, and it is also one of the equipment CRO companies with the highest net profit rate in China.
Shize Bio, an innovative cell therapy company, completed nearly 100 million yuan of Pre-A financing.
On September 8th, it was reported that Shize Biomedical Co., Ltd., a new generation of innovative stem cell therapy enterprise, recently officially announced the completion of nearly 100 million yuan Pre-A round of financing. This round of financing was jointly led by Qiming Venture Capital and Lilly Asia Ventures, followed by Daoyuan Capital and Jiacheng Capital, and all shareholders of Shize Biological Angel Wheel, Fengrui Capital, Yuansheng Venture Capital and TEDA Science Investment, followed suit. This round of financing is mainly used for the research and development of Shize Bio-core product pipeline and the construction of production workshop.
Shize Bio is committed to providing large-scale and low-cost stem cell therapy for major diseases such as Parkinson’s disease.
Several creatures completed nearly 100 million yuan in round B financing.
On September 8 th, Zhejiang Digital Biotechnology Co., Ltd. (hereinafter referred to as Digital Biotechnology) announced the completion of the B round of financing of nearly 100 million yuan. This round of financing was led by Guolian Investment, followed by Shuncheng Capital, Anyuan Fund and Chuangchuang Fund. After the completion of this round of financing, Digitalis will make great progress in the protection of external funds and the improvement of its own operational ability, which will provide sufficient guarantee for its persistent focus on tumor screening and the development, production and marketing of innovative products in the fields of maternal and child and reproductive health.
Neighbouring doctors completed tens of millions of yuan in Series A financing.
On September 9 th, neighboring medical fast medicine announced the completion of tens of millions of A round financing. This round of financing is invested by Jixianglei (Yantai) Medical Technology Co., Ltd., a wholly-owned subsidiary of Ruikang Medicine (002589.SZ) digital medical sector, and the funds will be used for market expansion, software development and upgrade, and team building.
Neighbourhood Medicine Express is a new retail empowerment solution provider of a pharmacy, which is committed to changing the traditional management mode of China pharmaceutical industry and helping it realize digital transformation with technical force.
Ruizheng Gene completed tens of millions of dollars in seed round financing.
On September 9, Ruizheng Gene (Suzhou) Co., Ltd. (abbreviated as Ruizheng Gene) announced that it has completed tens of millions of dollars in seed round financing. This round of financing was led by Junlian Capital, a well-known medical investment institution, and Cormorant followed the investment, which will be used to support the company’s R&D platform construction and the rapid advancement of pipelines.
Ruizheng Gene focuses on intracellular targets, including nuclear targets, and is committed to providing innovative drugs and treatment programs that can treat serious and even life-threatening congenital genetic diseases and acquired diseases for patients around the world.
Ge Rui surgical robot completed tens of millions of angel round financing.
On September 10th, Great Robotics, a precision imaging surgery robot, announced that it had completed tens of millions of angel round financing. This round of financing is exclusively led by Innolux Angel Fund, and the financing proceeds will be used for the core technology expansion and development of the company’s surgical robot platform, and then transformed into multiple product solutions.
Gerui Technology is an innovative medical robot company, which mainly develops a series of surgical robots according to the clinical needs and pain points based on the core technology platform of "precise image guidance" surgical robots.
Proton technology completed tens of millions of yuan series A financing.
On September 10th, Hangzhou Proton Technology Co., Ltd. completed the tens of millions of RMB Series A financing jointly led by Sigang Capital and Qirong Venture Capital, and the original shareholder Qikai Investment. This round of financing will be mainly used for product R&D investment, marketing and company operation, helping the company to continue to deepen the research and development of medical-grade vital signs monitoring technology and promote the development of artificial intelligence mobile medical industry.
Hangzhou Proton Technology Co., Ltd. is an innovative digital medical enterprise focusing on the research and development of wearable medical-grade vital signs monitoring technology. Its main business is to provide users with accurate, safe and convenient screening, diagnosis and health management services.
Biguan Bio completed tens of millions of A rounds of financing.
On September 10th, Day6 Biotech, a startup company developing a new generation of "microfluidic integrated machine" technology, announced the completion of tens of millions of RMB Series A financing, which was led by Songze Capital, followed by the old shareholders and Qingjie Capital, with Qingjie Capital as the exclusive financial advisor. The funds raised in this round will be used for clinical testing and NMPA registration of molecular POCT products with "on-demand inspection, low-cost consumables and one-step operation" developed by Biguan, and to expand the company’s R&D pipeline.
Mandi Medical, the first magnetocardiographic equipment factory in China, completed the A round financing of over 100 million yuan.
On September 10th, Mandi Medical announced the completion of the A round of financing exceeding 100 million yuan, which was jointly invested by National Science Development under the Chinese Academy of Sciences, Chinese Academy of Sciences Capital, Shanghai Microsystems Institute of Chinese Academy of Sciences, Shanghai Xinwei Group and Shanghai Guo Xin.
Mandi Medical Instrument (Shanghai) Co., Ltd. has mastered the domestic magnetocardiographic testing technology with independent intellectual property rights, and its equipment performance has reached the international level. In 2019, it became the first magnetocardiographic manufacturer in China to be approved with NMPA registration certificate.
Point technology won tens of millions of yuan in Series A financing.
On September 10th, it was reported that Diannei Technology, a medical artificial intelligence enterprise, had completed tens of millions of yuan of Series A financing, which was jointly completed by Trunk Road Fund and Empower Investment.
Founded in April 2016, Diannei Technology is one of the first enterprises to step into medical artificial intelligence image-aided diagnosis, focusing on the creation of AI lung cancer whole course solution.
LAM-Helio, a cancer early screening enterprise, completed hundreds of millions of yuan in financing.
On September 11th, LAM-Helio Group, which is committed to becoming a global leader in cancer early screening, has announced that it has completed financing of several hundred million yuan, with accumulated financing exceeding 1 billion yuan. Shareholders include Chinese Academy of Sciences Venture Capital, Chinese Academy of Sciences Parent Fund, Fulgent Genetics and other institutions and companies. The funds will be used to build the commercialization team and organization of liver cancer products, promote the Sino-US clinical approval of early screening products for intestinal cancer and lung cancer, and accelerate the optimization of early screening technologies for lung cancer and intestinal cancer with the National Cancer Center.
LAM-Helio is a life science enterprise group driven by "AI+ genomics", which focuses on early screening and early diagnosis of cancer.
smart manufacturing
Xiaomi Eco-chain Enterprise Shunzao Technology completed the $50 million Series B financing.
On September 8th, it was reported that Shunzao Technology, a technology enterprise focusing on the field of clean household appliances in Xiaomi’s ecological chain, recently completed a $50 million Series B financing. This round of investment was led by Baobi Industrial Chain Fund, followed by blue lagoon Capital, additional investment by Xiaomi Group and Shunwei Capital, and Yunmu Capital served as the exclusive financial advisor of the company. This round of financing will be mainly used for research and development of new technologies, iterative innovation of core products, global channel construction and the construction of fully automated factories for black technology.
Shunzao Technology was established in 2019. At present, it has built three categories of clean household appliances: handheld wireless vacuum cleaner, intelligent sweeping robot and intelligent washing machine.
Gartland completed hundreds of millions of RMB Series C financing.
On September 8th, it was reported that Gartland Microelectronics Technology (Shanghai) Co., Ltd. (hereinafter referred to as "Gartland"), a manufacturer of millimeter-wave radar chips with CMOS technology, had completed the C-round financing of several hundred million RMB. This round of financing was led by SDIC, with the participation of Langmafeng Venture Capital and Bank of Communications International, and the Huaxing New Economic Fund under Huaxing Capital continued to increase, with Huaxing Capital as the exclusive financial advisor.
Gartland was established in 2014, focusing on the research and development of millimeter-wave radar chips in CMOS technology, and it is the world’s leading provider of millimeter-wave radar chips.
Vibe, an intelligent hardware brand, has received a series of financing of tens of millions of dollars.
On September 7th, it was reported that Vibe (Sunlight Technology), an intelligent hardware brand, had recently completed the series A and A+ financing of tens of millions of dollars. The investors were Huachuang Capital and Sequoia China Seed Fund, and Light Source Capital served as the exclusive financial advisor for this round of financing. Previously, Vibe had received millions of dollars in financing from Challenger Capital, Xinyuan Capital and Jiuhe Venture Capital. This round of financing will be used for product research and development, supply chain integration and talent attraction.
Vibe combines the advantages of China’s supply chain with the potential enterprise market, and focuses on building a DTC(Direct To Customer) brand in the field of To B combining software and hardware.
Guona Semiconductor completed tens of millions of A+ rounds of financing.
On September 10th, it was reported that Guona Semiconductor, a developer of semiconductor components, recently announced the completion of tens of millions of A+ rounds of financing. The investors included Zhongxin Capital, Shenzhen Tianxia Future and Huada Microelectronics, the largest shareholder of Tongfu Microelectronics.
Guona Semiconductor was established in 2020, focusing on the field of integrated circuit transmission, and its main business is semiconductor transmission equipment modules and parts.
TMT
Craftsman Technology completed the B2 round of financing of nearly RMB 100 million.
On September 9th, it was reported that Craftsman Technology, a digital commercial real estate service provider, recently completed a B2 round of financing of nearly RMB 100 million. This round was led by Zhixin Capital, and Yibai Capital served as the exclusive financial advisor. The funds will be mainly used for research and development and business expansion.
Founded in 2015, Craftsman Technology has been focusing on the real estate technology track.
Youbi Technology completed tens of millions of A round financing.
On September 9, Ubisoft, a smart IOT solution provider in the energy industry, announced that it had recently completed tens of millions of RMB Series A financing, which was exclusively invested by Jingwei Venture Capital. This round of financing will be mainly used for the company’s continuous expansion of new product lines such as online monitoring of smart grid, intelligent operation and maintenance of new energy and energy storage monitoring, and continue to dig deep into domestic and foreign markets, and further improve the team structure.
Youbi Technology focuses on empowering cutting-edge technologies such as AIoT, deep learning and neural networks to industries such as power, energy and rail transit, and providing end-to-end "AI+" products, services and overall solutions to customers around the world.
Intelligent marketing platform Stepone Jizhi Technology completed 100 million yuan Series B financing.
On September 9 th, Stepone Jizhi Technology (hereinafter referred to as "Jizhi Technology"), a one-stop intelligent marketing customer acquisition platform, announced the completion of 100 million yuan Series B financing. This round of financing was led by SIG Heiner Asia Venture Capital, and Taiyue Wutong Capital, a fund of listed company Shenzhou Taiyue, followed suit. At the same time, all the old shareholders such as Guangsu China, Xinyi Capital and Xiang Hailong continued to follow suit.
Steepone Jizhi Technology is a leading intelligent customer service provider in China, providing full-process intelligent marketing services for To B enterprises based on Al big data technology.
E-PORTS was led by Jinshajiang United Capital in the B1 round of financing.
On September 6th, E-PORTS, the Internet platform of shipping industry, announced the completion of tens of millions of B1 round financing. This round of financing was led by Jinshajiang United Capital, with Index Capital as the exclusive financial advisor. The financing funds will be mainly used for system research and development, team building and market expansion.
E-PORTS takes "one-click access to world-class shipping services" as its mission, and is committed to providing online and offline world-class shipping services for global ships and port service solutions for global merchant ships.
(Author: Zhao Na Editor: Lin Kun)